Justine Ra, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/justinera/ Hard data and deep insights on clinical trials strategy & operations Fri, 25 Oct 2024 11:22:15 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2022/01/cropped-Clinical-Trials-Arena-32x32.png Justine Ra, Author at Clinical Trials Arena https://www.clinicaltrialsarena.com/author/justinera/ 32 32 Adapting diabetes clinical trials to embrace underrepresented communities https://www.clinicaltrialsarena.com/features/adapting-diabetes-clinical-trials-to-embrace-underrepresented-communities/ Fri, 25 Oct 2024 11:22:00 +0000 https://www.clinicaltrialsarena.com/uncategorized/adapting-diabetes-clinical-trials-to-embrace-underrepresented-communities/ Solutions are needed to bridge gaps in communication that can prevent underserved communities from entering diabetes clinical trials.

The post Adapting diabetes clinical trials to embrace underrepresented communities appeared first on Clinical Trials Arena.

]]> The post Adapting diabetes clinical trials to embrace underrepresented communities appeared first on Clinical Trials Arena.

]]> Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome https://www.clinicaltrialsarena.com/features/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome/ Mon, 07 Oct 2024 07:00:00 +0000 Biosensors and biomarkers could provide valuable secondary data, but challenges remain with implementation and data collection.

The post Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome appeared first on Clinical Trials Arena.

]]> The post Ushering in a new era of fit-for-purpose clinical endpoints for Rett syndrome appeared first on Clinical Trials Arena.

]]> Alzheimer’s heterogeneity necessitates diverse enrollment in clinical trials https://www.clinicaltrialsarena.com/features/alzheimers-heterogeneity-necessitates-diverse-enrollment-in-clinical-trials/ Thu, 12 Sep 2024 20:23:40 +0000 https://www.clinicaltrialsarena.com/features/alzheimers-heterogeneity-necessitates-diverse-enrollment-in-clinical-trials/ Clinical trials need to evolve screening criteria to include diverse patient groups as more Alzheimer's disease drugs become available.

The post Alzheimer’s heterogeneity necessitates diverse enrollment in clinical trials appeared first on Clinical Trials Arena.

]]> The post Alzheimer’s heterogeneity necessitates diverse enrollment in clinical trials appeared first on Clinical Trials Arena.

]]> Pan Cancer T looks to increase T cell durability with next-gen TCR-T https://www.clinicaltrialsarena.com/news/pan-cancer-t-looks-to-increase-t-cell-durability-with-next-gen-tcr-t/ Mon, 09 Sep 2024 16:17:01 +0000 https://www.clinicaltrialsarena.com/uncategorized/pan-cancer-t-looks-to-increase-t-cell-durability-with-next-gen-tcr-t/ The biotech, currently in preclinical stages, aims to advance its lead candidate for melanoma and TNBC to clinical studies in 2026.

The post Pan Cancer T looks to increase T cell durability with next-gen TCR-T appeared first on Clinical Trials Arena.

]]> The post Pan Cancer T looks to increase T cell durability with next-gen TCR-T appeared first on Clinical Trials Arena.

]]> RegenxBio touts positive data for rare disease drug RGX-121 https://www.clinicaltrialsarena.com/news/regenxbio-touts-positive-data-for-rare-disease-drug-rgx-121/ Tue, 03 Sep 2024 17:17:19 +0000 https://www.clinicaltrialsarena.com/uncategorized/regenxbio-touts-positive-data-for-rare-disease-drug-rgx-121/ RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.

The post RegenxBio touts positive data for rare disease drug RGX-121 appeared first on Clinical Trials Arena.

]]> The post RegenxBio touts positive data for rare disease drug RGX-121 appeared first on Clinical Trials Arena.

]]> DMD clinical studies evolve with emphasis on building designs around relevant endpoints  https://www.clinicaltrialsarena.com/features/dmd-clinical-studies-evolve-with-emphasis-on-building-designs-around-relevant-endpoints/ Fri, 30 Aug 2024 12:50:20 +0000 https://www.clinicaltrialsarena.com/features/dmd-clinical-studies-evolve-with-emphasis-on-building-designs-around-relevant-endpoints/ Endpoint selection needs to be made considering the heterogeneous Duchenne muscular dystrophy population.

The post DMD clinical studies evolve with emphasis on building designs around relevant endpoints  appeared first on Clinical Trials Arena.

]]> The post DMD clinical studies evolve with emphasis on building designs around relevant endpoints  appeared first on Clinical Trials Arena.

]]> Pfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readout https://www.clinicaltrialsarena.com/news/pfizer-and-biontechs-covid-19-flu-combination-vaccine-falters-in-phase-iii-readout/ Fri, 16 Aug 2024 20:28:24 +0000 https://www.clinicaltrialsarena.com/uncategorized/pfizer-and-biontechs-covid-19-flu-combination-vaccine-falters-in-phase-iii-readout/ While the vaccine demonstrated high responses for neutralizing influenza A titers, it failed to show sufficient efficacy against influenza B.

The post Pfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readout appeared first on Clinical Trials Arena.

]]> The post Pfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readout appeared first on Clinical Trials Arena.

]]> Pfizer touts positive topline data for RSV vaccine Abrysvo https://www.clinicaltrialsarena.com/news/pfizer-touts-positive-topline-data-for-rsv-vaccine-abrysvo/ Mon, 12 Aug 2024 15:49:30 +0000 https://www.clinicaltrialsarena.com/uncategorized/pfizer-touts-positive-topline-data-for-rsv-vaccine-abrysvo/ Abrysvo was found to be safe in immunocompromised adults at risk for developing RSV-associated lower respiratory tract disease.

The post Pfizer touts positive topline data for RSV vaccine Abrysvo appeared first on Clinical Trials Arena.

]]> The post Pfizer touts positive topline data for RSV vaccine Abrysvo appeared first on Clinical Trials Arena.

]]> AAIC 2024: Eisai presents positive long-term data with Leqembi https://www.clinicaltrialsarena.com/news/aaic-2024-eisai-presents-positive-long-term-data-with-leqembi/ Thu, 01 Aug 2024 16:40:04 +0000 https://www.clinicaltrialsarena.com/uncategorized/aaic-2024-eisai-presents-positive-long-term-data-with-leqembi/ Patients treated with Leqembi over three years have demonstrated a slowing of Alzheimer’s disease progression.

The post AAIC 2024: Eisai presents positive long-term data with Leqembi appeared first on Clinical Trials Arena.

]]> The post AAIC 2024: Eisai presents positive long-term data with Leqembi appeared first on Clinical Trials Arena.

]]> AAIC 2024: The evolution of Alzheimer’s clinical trials https://www.clinicaltrialsarena.com/news/aaic-2024-the-evolution-of-alzheimers-clinical-trials/ Mon, 29 Jul 2024 18:15:59 +0000 https://www.clinicaltrialsarena.com/uncategorized/aaic-2024-the-evolution-of-alzheimers-clinical-trials/ Clinical trial trends point to studying combination therapies and lifestyle changes using alternate designs in Alzheimer’s research.

The post AAIC 2024: The evolution of Alzheimer’s clinical trials appeared first on Clinical Trials Arena.

]]> The post AAIC 2024: The evolution of Alzheimer’s clinical trials appeared first on Clinical Trials Arena.

]]>